FDA Approves Genentech’s RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology By Araceli Richardson|2020-08-18T00:57:59-07:00June 22, 2017|
Flex Pharma Announces Pricing Of Initial Public Offering By Araceli Richardson|2020-08-18T00:57:59-07:00January 28, 2015|
FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency By Araceli Richardson|2020-08-18T00:57:59-07:00September 12, 2014|
Halozyme Announces Roche Marketing Authorization For MabThera SC For Patients With Common Forms Of Non-Hodgkin Lymphoma In European Union By Araceli Richardson|2020-08-18T00:57:59-07:00March 28, 2014|
Roche’s new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer By Araceli Richardson|2020-08-18T00:58:00-07:00September 2, 2013|
Halozyme Announces Positive Opinion from CHMP On Roche’s Herceptin SC for European Approval By Araceli Richardson|2020-08-18T00:58:00-07:00June 28, 2013|
Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union By Araceli Richardson|2020-08-18T00:58:00-07:00March 22, 2013|
Bionomics Acquires US-Based Cancer Stem Cell Company Eclipse Therapeutics By Araceli Richardson|2020-08-18T00:58:00-07:00September 17, 2012|
Halozyme Therapeutics, Inc. And Baxter Healthcare Corporation Announce FDA Approval Of Hylenex By Araceli Richardson|2020-08-18T00:58:00-07:00December 5, 2005|
